In ₹ Crore except Per Share Latest Annual	PPLPHARMA FY26	DIVISLAB FY26	SYNGENE FY26	GLAND FY26	Peer Average
Valuation — at last close
P/E	—	99.89×	50.65×	◆ 49.31×	66.61×
P/B	3.75×	15.28×	◆ 3.32×	4.89×	7.83× -52%
EV/EBITDA	37.73×	73.43×	◆ 16.09×	29.17×	39.57× -5%
Market Cap	₹30,628 Cr	₹2.56L Cr	₹16,060 Cr	₹50,655 Cr	₹1.08L Cr -72%
Growth
Revenue CAGR 3Y	7.79%	10.78%	5.40%	◆ 21.06%	12.41% -37%
Revenue CAGR 5Y	—	8.67%	11.35%	◆ 13.18%	11.07%
Net Income CAGR 3Y	—	◆ 12.09%	-11.98%	9.57%	3.23%
Revenue YoY (latest Q)	◆ 28.05%	27.80%	-8.55%	19.57%	12.94% +117%
Net Income YoY (latest Q)	◆ 105.07%	65.50%	-52.01%	47.09%	20.19% +420%
Profitability
EBITDA Margin	10.39%	◆ 32.59%	24.57%	25.34%	27.50% -62%
Net Income Margin	-3.68%	◆ 24.32%	8.47%	15.98%	16.26% -123%
Return on Common Equity	-4.00%	◆ 16.19%	6.62%	10.53%	11.11% -136%
Return on Capital Employed	0.72%	◆ 17.80%	8.54%	11.73%	12.69% -94%
Return on Assets	-1.94%	◆ 13.89%	4.57%	8.66%	9.04% -121%
Credit & Quality
Total Debt/Equity	0.67×	◆ 0.00×	0.00×	0.02×	0.01× +9950%
Interest Coverage	0.27×	◆ 129.48×	9.54×	36.24×	58.42× -100%
Scale — latest FY
Revenue / Total Income	₹8,869 Cr	₹10,560 Cr	₹3,739 Cr	₹6,431 Cr	₹6,910 Cr +28%
Net Income	−₹326 Cr	₹2,568 Cr	₹317 Cr	₹1,027 Cr	₹1,304 Cr -125%
Total Assets	₹17,965 Cr	₹20,033 Cr	₹7,055 Cr	₹12,511 Cr	₹13,200 Cr +36%
EPS	₹-2.46	₹96.75	₹7.87	₹62.35	₹55.66 -104%
Book Value per Share	₹61.5	₹632.49	₹120.11	₹628.67	₹460.42 -87%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.